poisar

Stocks · News reference

ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est

Aug 5, 2026, 8:24 PMBenzinga Newsdesk

ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ADMA
Source
benzinga
Observed
Aug 5, 2026, 8:24 PM
Checked
Aug 5, 2026, 8:24 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. Aug 5, 2026, 2:57 AMKahn Swick & Foti, Llc

    ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

    Kahn Swick & Foti, LLC announces a class action securities lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges the company and its executives failed to disclose material information, including undisclosed related party transactions, channel stuffing, and inadequate internal controls. The application deadline to request lead plaintiff status is August 10, 2026.

    Read original at globenewswire-inc
    ADMA